Emory University

Belantamab mafodotin produced sustained clinically meaningful responses in patients with relapsed or refractory multiple myeloma, according to findings from the DREAMM-2 study presented at ASCO.

Transoral resection followed by low-dose radiation appeared safe and effective for patients with p16-positive oropharynx cancer, according to results of a randomized phase 2 trial presented during the ASCO20 Virtual Scientific Program.

Data from clinical trials show that findings often do not apply to minority populations, and trialists must adopt cultural competency practices to recruit and retain black participants, according to a speaker.

Nivolumab plus ipilimumab continued to provide long-term OS benefits compared with chemotherapy as initial treatment for advanced non-small cell lung cancer, according to study results presented during the ASCO20 Virtual Scientific Program.

Five physicians received Hastings Center Cunniff-Dixon Physician Awards in recognition of their exemplary service to patients near the end of life.

The HHS assistant secretary for health and the U.S. surgeon general are asking health care providers to repurpose and share ventilators, cancel elective surgeries and transfer equipment and personnel to areas hardest hit by the COVID-19 pandemic.

Fewer medical trainees are entering the field of HIV, leaving a shortage in the workforce that is likely to get worse, experts said. The trend coincides with slowed progress in reducing new infections, and likely complicates a lofty new federal plan to end the U.S. epidemic in 10 years.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.

Belantamab mafodotin, an investigational anti-B-cell maturation antigen monoclonal antibody-drug conjugate, demonstrated clinically meaningful response rates among patients with heavily pretreated multiple myeloma, according to results of the randomized phase 2 DREAMM-2 trial published in Lancet Oncology.

ORLANDO — Oral supplementation with arginine resulted in faster resolution of pain associated with vaso-occlusive episodes among younger patients with sickle cell disease, according to the results of a randomized phase 2 trial presented at ASH Annual Meeting and Exposition.